These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 21788224)
1. A randomized study of a monoclonal antibody (pagibaximab) to prevent staphylococcal sepsis. Weisman LE; Thackray HM; Steinhorn RH; Walsh WF; Lassiter HA; Dhanireddy R; Brozanski BS; Palmer KG; Trautman MS; Escobedo M; Meissner HC; Sasidharan P; Fretz J; Kokai-Kun JF; Kramer WG; Fischer GW; Mond JJ Pediatrics; 2011 Aug; 128(2):271-9. PubMed ID: 21788224 [TBL] [Abstract][Full Text] [Related]
2. Phase 1/2 double-blind, placebo-controlled, dose escalation, safety, and pharmacokinetic study of pagibaximab (BSYX-A110), an antistaphylococcal monoclonal antibody for the prevention of staphylococcal bloodstream infections, in very-low-birth-weight neonates. Weisman LE; Thackray HM; Garcia-Prats JA; Nesin M; Schneider JH; Fretz J; Kokai-Kun JF; Mond JJ; Kramer WG; Fischer GW Antimicrob Agents Chemother; 2009 Jul; 53(7):2879-86. PubMed ID: 19380597 [TBL] [Abstract][Full Text] [Related]
3. Safety and pharmacokinetics of a chimerized anti-lipoteichoic acid monoclonal antibody in healthy adults. Weisman LE; Fischer GW; Thackray HM; Johnson KE; Schuman RF; Mandy GT; Stratton BE; Adams KM; Kramer WG; Mond JJ Int Immunopharmacol; 2009 May; 9(5):639-44. PubMed ID: 19268719 [TBL] [Abstract][Full Text] [Related]
4. Anti-lipoteichoic acid monoclonal antibody (pagibaximab) studies for the prevention of staphylococcal bloodstream infections in preterm infants. Patel M; Kaufman DA Expert Opin Biol Ther; 2015 Apr; 15(4):595-600. PubMed ID: 25736524 [TBL] [Abstract][Full Text] [Related]
5. Clinical trial of safety and efficacy of INH-A21 for the prevention of nosocomial staphylococcal bloodstream infection in premature infants. DeJonge M; Burchfield D; Bloom B; Duenas M; Walker W; Polak M; Jung E; Millard D; Schelonka R; Eyal F; Morris A; Kapik B; Roberson D; Kesler K; Patti J; Hetherington S J Pediatr; 2007 Sep; 151(3):260-5, 265.e1. PubMed ID: 17719934 [TBL] [Abstract][Full Text] [Related]
6. Growth, efficacy, and safety of feeding an iron-fortified human milk fortifier. Berseth CL; Van Aerde JE; Gross S; Stolz SI; Harris CL; Hansen JW Pediatrics; 2004 Dec; 114(6):e699-706. PubMed ID: 15545616 [TBL] [Abstract][Full Text] [Related]
7. Is bloodstream infection preventable among premature infants? A tale of two cities. Aly H; Herson V; Duncan A; Herr J; Bender J; Patel K; El-Mohandes AA Pediatrics; 2005 Jun; 115(6):1513-8. PubMed ID: 15930211 [TBL] [Abstract][Full Text] [Related]
8. A blinded, randomized, multicenter study of an intravenous Staphylococcus aureus immune globulin. Benjamin DK; Schelonka R; White R; Holley HP; Bifano E; Cummings J; Adcock K; Kaufman D; Puppala B; Riedel P; Hall B; White J; Cotton CM; J Perinatol; 2006 May; 26(5):290-5. PubMed ID: 16598296 [TBL] [Abstract][Full Text] [Related]
9. Intravenous immune globulin for the prevention of nosocomial infection in low-birth-weight neonates. The Multicenter Group for the Study of Immune Globulin in Neonates. Baker CJ; Melish ME; Hall RT; Casto DT; Vasan U; Givner LB N Engl J Med; 1992 Jul; 327(4):213-9. PubMed ID: 1614462 [TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis. Rice TW; Wheeler AP; Bernard GR; Vincent JL; Angus DC; Aikawa N; Demeyer I; Sainati S; Amlot N; Cao C; Ii M; Matsuda H; Mouri K; Cohen J Crit Care Med; 2010 Aug; 38(8):1685-94. PubMed ID: 20562702 [TBL] [Abstract][Full Text] [Related]
11. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Maini RN; Breedveld FC; Kalden JR; Smolen JS; Davis D; Macfarlane JD; Antoni C; Leeb B; Elliott MJ; Woody JN; Schaible TF; Feldmann M Arthritis Rheum; 1998 Sep; 41(9):1552-63. PubMed ID: 9751087 [TBL] [Abstract][Full Text] [Related]
12. Once-weekly liposomal amphotericin B as Candida prophylaxis in very low birth weight premature infants: a prospective, randomized, open-label, placebo-controlled pilot study. Arrieta AC; Shea K; Dhar V; Cleary JP; Kukreja S; Morris M; Vargas-Shiraishi OM; Ashouri N; Singh J Clin Ther; 2010 Feb; 32(2):265-71. PubMed ID: 20206784 [TBL] [Abstract][Full Text] [Related]
13. [Preventive antibiotic administration for prevention of nosocomial septicemia in very small premature infants (VLBW infants)--preventive vancomycin administration against infections with coagulase negative streptococci--prevention of translocation with oral cefixime therapy in intestinal colonization with pathogenic gram-negative pathogens]. Möller JC; Rossa M; Nachtrodt G; Richter A; Tegtmeyer FK Klin Padiatr; 1993; 205(3):140-4. PubMed ID: 8350584 [TBL] [Abstract][Full Text] [Related]
14. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. Ziegler EJ; Fisher CJ; Sprung CL; Straube RC; Sadoff JC; Foulke GE; Wortel CH; Fink MP; Dellinger RP; Teng NN N Engl J Med; 1991 Feb; 324(7):429-36. PubMed ID: 1988827 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study. Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648 [TBL] [Abstract][Full Text] [Related]
16. A phase I/II trial of high-dose erythropoietin in extremely low birth weight infants: pharmacokinetics and safety. Juul SE; McPherson RJ; Bauer LA; Ledbetter KJ; Gleason CA; Mayock DE Pediatrics; 2008 Aug; 122(2):383-91. PubMed ID: 18676557 [TBL] [Abstract][Full Text] [Related]
17. Multicenter study to determine antibody concentrations and assess the safety of administration of INH-A21, a donor-selected human Staphylococcal immune globulin, in low-birth-weight infants. Capparelli EV; Bloom BT; Kueser TJ; Oelberg DG; Bifano EM; White RD; Schelonka RL; Pearlman SA; Patti J; Hetherington SV Antimicrob Agents Chemother; 2005 Oct; 49(10):4121-7. PubMed ID: 16189088 [TBL] [Abstract][Full Text] [Related]
18. Preterm infants with low immunoglobulin G levels have increased risk of neonatal sepsis but do not benefit from prophylactic immunoglobulin G. Sandberg K; Fasth A; Berger A; Eibl M; Isacson K; Lischka A; Pollak A; Tessin I; Thiringer K J Pediatr; 2000 Nov; 137(5):623-8. PubMed ID: 11060526 [TBL] [Abstract][Full Text] [Related]
19. A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease. Reinisch W; Hommes DW; Van Assche G; Colombel JF; Gendre JP; Oldenburg B; Teml A; Geboes K; Ding H; Zhang L; Tang M; Cheng M; van Deventer SJ; Rutgeerts P; Pearce T Gut; 2006 Aug; 55(8):1138-44. PubMed ID: 16492717 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of a phospholipid emulsion (GR270773) in Gram-negative severe sepsis: results of a phase II multicenter, randomized, placebo-controlled, dose-finding clinical trial. Dellinger RP; Tomayko JF; Angus DC; Opal S; Cupo MA; McDermott S; Ducher A; Calandra T; Cohen J; Crit Care Med; 2009 Nov; 37(11):2929-38. PubMed ID: 19770753 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]